Clinical trial
AG2037 in Treating Patients With Advanced, Metastatic, or Recurrent Solid Tumors
NCT00017524 · University of Alabama at Birmingham, Other · Completed
Key facts
| NCT number | NCT00017524 |
|---|---|
| Title | AG2037 in Treating Patients With Advanced, Metastatic, or Recurrent Solid Tumors |
| Official title | A Phase I Dose-Escalation Study of AG2037 Administered Once Weekly for Three Weeks to Patients With Advanced Cancer |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | pelitrexol |
| Enrollment | 22 |
| Start date | Mar 1, 2001 |
| Completion | Nov 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Dec 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: